Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy

Journal of Clinical Microbiology

Volumn 48, Issue 2, 2010, Pages 631-634

  Schildgen, Oliver ^a   Olotu, Cynthia ^c   Funk, Anneke ^c,f   Zöllner, Bernhard ^b   Helm, Martin ^d   Rockstroh, Jürgen Kurt ^e   Sirma, Hüseyin ^c  

^a Kliniken der Stadt Koln   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^d Practice Abelein/Helm   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; TENOFOVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE;

ADENINE; ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHOSPHONIC ACIDS; SELECTION, GENETIC; SEQUENCE ALIGNMENT; TREATMENT FAILURE; VIREMIA; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 75649094924     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01073-09     Document Type: Article

References (20)

1. Angus, P., R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, A. Ayres, A. Bartholomeusz, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
2. Bartholomeusz, A., M. Kuiper, P. Angus, A. Ayres, M. Littlejohn, D. Colledge, N. Warner, and S. Locarnini. 2006. Molecular analysis of HBV polymerase mutations associated with dual adefovir and lamivudine resistance. J. Hepatol. 44:S179-S179.
3. Chang, T. T., and C. L. Lai. 2006. Hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med. 355:322-323.
4. Curtis, M., Y. Zhu, and K. Borroto-Esoda. 2007. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J. Infect. Dis. 196:1483-1486.
5. Degertekin, B., and A. S. Lok. 2009. Indications for therapy in hepatitis B. Hepatology 49:S129-S137.
6. Fontana, R. J. 2009. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49:S185-S195.
7. Hadziyannis, S. J., N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:800-807.
8. Lai, C. L., D. Shouval, A. S. Lok, T. T. Chang, H. Cheinquer, Z. Goodman, D. DeHertogh, R. Wilber, R. C. Zink, A. Cross, R. Colonno, and L. Fernandes. 2006. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354:1011-1020.
9. Liu, C. J., B. F. Chen, P. J. Chen, M. Y. Lai, W. L. Huang, J. H. Kao, and D. S. Chen. 2006. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J. Infect. Dis. 193:1258-1265.
10. Lucifora, J., D. Durantel, L. Belloni, L. Barraud, S. Villet, I. E. Vincent, S. Margeridon-Thermet, O. Hantz, A. Kay, M. Levrero, and F. Zoulim. 2008. Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector. J. Gen. Virol. 89:1819-1828.
11. Marcellin, P., T. T. Chang, S. G. Lim, M. J. Tong, W. Sievert, M. L. Shiffman, L. Jeffers, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:808-816.
12. Nassal, M., K. Dallmeier, U. Schultz, and D. Sun. 2005. Phenotyping hepatitis B virus variants: from transfection towards a small animal in vivo infection model. J. Clin. Virol. 34(Suppl. 1):S89-S95.
13. Osiowy, C., J. P. Villeneuve, E. J. Heathcote, E. Giles, and J. Borlang. 2006. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J. Clin. Microbiol. 44:1994-1997.
14. Schildgen, O., M. Fiedler, U. Dahmen, J. Li, B. Lohrengel, M. Lu, and M. Roggendorf. 2006. Fluctuation of the cytokine expression in the liver during the chronic woodchuck hepatitis virus (WHV) infection is not related to viral load. Immunol. Lett. 102:31-37.
15. Schildgen, O., H. Sirma, A. Funk, C. Olotu, U. C. Wend, H. Hartmann, M. Helm, J. K. Rockstroh, W. R. Willems, H. Will, and W. H. Gerlich. 2006. Variant of hepatitis B virus with primary resistance to adefovir. N Engl. J. Med. 354:1807-1812.
16. Villet, S., G. Billioud, C. Pichoud, J. Lucifora, O. Hantz, C. Sureau, P. Deny, and F. Zoulim. 2009. In vitro characterization of viral fitness of therapyresistant hepatitis B variants. Gastroenterology 136:168-176.
17. Villet, S., C. Pichoud, G. Billioud, L. Barraud, S. Durantel, C. Trepo, and F. Zoulim. 2008. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J. Hepatol. 48:747-755.
18. Wang, Y. Z., J. H. Xiao, L. H. Ruan, H. Y. Zhang, M. Chen, X. K. Pu, H. Y. Shen, and G. X. Wu. 2009. Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay. Clin. Chim. Acta 408:70-74.
19. WHO. 2000. Hepatitis B. Fact sheet no. 204. WHO, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs204/en/.
20. Zoulim, F., and S. Locarnini. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-1608.